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Abstract
Background:  The purpose of this study was to determine risk factors for development of
malignant ascites and its prognostic significance in patients with pancreatic cancer.
Methods: A prospective database was queried to identify patients with pancreatic cancer who
develop ascites. Stage at presentation, size, and location of primary tumor, treatment received and
length of survival after onset of ascites were determined.
Results:  A total of 15 patients were identified. Of which 4 patients (1 stage II, 3 stage III)
underwent pancreaticoduodenectomy and manifested with ascites 2, 3, 24 and 47 months after
surgery (tumor size 2.9 ± 1.32 cm). All but one of the remaining 11 patients (tumor size 4.4 ± 3.38
cm) presented with metastatic disease, and all developed malignant ascites 9 months after diagnosis,
dying 2 months later. Resected patients lived longer before the onset of ascites, but not after.
Conclusion:  Once diagnosed, ascites in pancreatic cancer patients heralds imminent death.
Limited survival should be considered when determining the aggressiveness of further intervention.
Background
Pancreatic cancer is the 5th most common gastrointestinal
(GI) malignancy but the third most common cause of
death among all GI cancers [1]. Almost all patients with
pancreatic cancer ultimately die of it, usually within 6
months of diagnosis [2]. The vast majority of these
patients are ineligible for surgical therapy at the time of
diagnosis due to metastatic spread or local invasion and
death usually occurs by inanition rather than gross tumor
burden. Aggressive chemotherapeutic regimens are gener-
ally highly toxic and prolong life by weeks, rather than
months [3]. Most patients with unresectable pancreatic
cancer die of their disease before completing a standard
course of therapy.
Common manifestations of end stage pancreatic cancer
include: gastric outlet obstruction due to tumor ingrowth
to the duodenum, cachexia, deep venous thrombosis
(Trousseau's phenomenon), anasarca and ascites. Ascites
manifests in only 20% of pancreatic cancer patients and
its cause is multifactorial [4]. It can occur due to obstruc-
tion of diaphragmatic lymphatics, increased production
of exudate by the tumor itself and production of osmoti-
cally active peptides that alter vascular permeability to
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favor ascites formation [5]. In most series, over half of the
time, cancer cells can not be identified in a paracentesis
sample [4,6]. As such, in this setting, the ascites may not
be malignant in the purest sense however; it is undoubt-
edly due to the cancer even if cancer cells cannot be found
in the fluid. Other authors have suggested methods other
than cytology to determine the nature of ascites such as
ascites/serum albumin gradients or presence of various
substances such as telemorase or human gonadotropin-β
in the ascites [7-9]. We have noted that regardless of
whether ascites can be proven to be malignant cytologi-
cally, it is usually the final manifestation of a uniformly
fatal diagnosis.
Malignant ascites can be managed for extended periods in
patients with other types of cancer such as those of gyne-
cologic, gastric or colonic origin [10]. We have noted,
however, after treating multiple patients with both
resected and non-resected pancreatic cancer on various
protocols at our institution that regardless of the type of
intervention employed, the new onset of ascites in these
patients usually heralded imminent demise. The purpose
of this study, therefore, was to examine this phenomenon
and determine the exact prognostic implications of new
onset ascites to better guide subsequent treatment and to
counsel patients more effectively. We hypothesized that
new onset ascites in patients with pancreatic cancer would
be associated with those factors commonly attributed to
the final stages of the disease and that death would soon
follow its manifestation.
Patients and methods
A prospective database involving all patients treated on
protocols for pancreatic cancer at our institution was
begun in 2001. All patients were entered into this data-
base with Institutional Review Board (IRB) approval after
giving informed consent. The database chronicles each
patient's course from the time of enrollment into a proto-
col to the time of death, regardless of whether they com-
plete the protocol. Patients who presented with, or
developed ascites after having been diagnosed with pan-
creatic cancer were included in this analysis. Chart review
was undertaken to gain basic demographic data including
patient age, gender, tumor characteristics such as size, and
location. Stage and tumor marker levels were determined
at three different time points: presentation, onset of
ascites and just prior to death.
After identifying all patients with ascites, patients were
divided into two groups: those having undergone resec-
tion and those managed non-operatively. The type of
treatment employed for both the primary tumor and the
ascites was noted. The incidence of malignant cells in the
ascites was noted as was the method by which the ascites
was diagnosed. Overall survival, ascites free interval and
survival with ascites were determined for the entire
cohort. Survival after therapeutic intervention was also
noted after separating the patients into those undergoing
no treatment, diuretics alone, paracentesis alone, diuretics
and paracentesis or peritoneovenous shunting. Double
valved Denver® (Denver Biomaterials, Denver Colorado)
peritoneovenous shunts were employed in all patients
undergoing this type of treatment. In cases where a
patient's status was unknown, attempts were made to con-
tact the patient or their family. All data is current to March
of 2005.
The database was queried to determine whether any spe-
cific predictors of risk of developing malignant ascites
could be gleaned. Linear regression was utilized to deter-
mine whether tumor size, lymph node status, margin sta-
tus (if resected), grade, stage at presentation, tumor
location, stage at onset of ascites, presence of neural or
lymphovascular invasion, or type of therapy (chemother-
apy v. chemoradiation) would predict the onset of ascites.
Where appropriate, tumor size and survival characteristics
were compared using a two tailed Student's T-test. Signif-
icance was accepted with 95% probability.
Results
Demographics and basic tumor characteristics
A total of 120 patients were enrolled in protocols at our
institution between 2001 and late 2004. Of these 120
patients, 15 were identified who developed ascites after
the diagnosis of pancreatic cancer. All but two were men
and average age was consistent with that which is com-
monly observed in this disease process. Almost all tumors
were located in the head of the gland, one patient present-
ing with intermittent jaundice, an elevated carbohydrate
antigen 19-9 (CA 19-9) level and no radiographic evi-
dence of disease was diagnosed with peritoneal carcino-
matosis and ascites at the time of celiotomy; his primary
tumor was occult. Four patients underwent resection of
their tumors and although their tumors were almost 1.5
cm smaller at presentation than those patients not under-
going resection, this difference was not statistically signif-
icant. Ascites was most commonly diagnosed by physical
examination followed by radiographically and then as an
incidental finding at celiotomy. In these patients, ascites
manifested between the time of their preoperative com-
puted tomography (CT) scan suggesting resectability and
the time of their exploration and none were resected.
Demographics for the entire group of patients are
depicted in Table 1.
Cytology
All patients underwent paracentesis or intraoperative col-
lection of fluid for cytologic analysis. Only 5 of the 15
patients in this study had malignant cells in their ascites.World Journal of Surgical Oncology 2006, 4:16 http://www.wjso.com/content/4/1/16
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Figure 1 is a representative photomicrograph of a positive
cytologic preparation in one such patient.
Survival
Survival for all patients, those undergoing resection and
those receiving non-operative management of their cancer
is summarized in Table 2. Overall survival was just less
than one year for the group as a whole. Survival in
resected patients was near significantly longer (p = 0.06)
than non-resected patients. Ascites free survival was signif-
icantly longer in patients undergoing resection but once
ascites became manifest, survival was no different in
patients who had undergone resection than those not
undergoing resection. Once ascites developed, patients
treated non-operatively lived about 7 weeks longer than
those that developed ascites after pancreaticoduodenec-
tomy. Overall survival after ascites developed was slightly
over 2 months.
Survival based on treatment rendered for ascites
Patients managed with diuretics alone or peritoneov-
enous shunts seemed to do better in this group than those
receiving no treatment or paracentesis with or without
diuretics although none of these intervals were statistically
different. Table 3 chronicles outcome based on treatment
method.
Stage and tumor markers
Patients were evenly distributed between stages at the
time of presentation but quickly progressed to Stage IV
disease at the time their ascites was discovered. This
includes those patients who were not automatically staged
as metastatic because of positive fluid cytology. Ascites
rarely occurred in patients who were not advanced stage.
Tumor markers were higher at diagnosis than at the onset
of ascites reflecting again the advanced nature of the dis-
ease at the time it was discovered. At presentation of
ascites, tumor markers were lower, but quickly reached
their highest point at those levels drawn just before each
patient's death. Wide variations in levels of tumor markers
at each interval resulted in no statistical difference in CA
19-9 at various time points.
Multivariate analysis
Linear regression revealed no characteristics to predict the
onset of ascites. Tumor size approached but given the size
of the overall database, did not reach statistical signifi-
cance. Location, lymph node status, histologic grade, and
type of or utilization of chemotherapy or chemoradio-
therapy neither predicted nor prevented new onset ascites.
Presence of unexplained free fluid at the time of celiotomy
always predicted eventual onset of ascites, but this was not
categorized as "ascites" in the database and, as such, was
not predictive.
Discussion
Pancreatic cancer remains a diagnostic and therapeutic
challenge. No effective medical therapies have emerged,
despite rapid advancements in targeted chemotherapeutic
agents. Patients with pancreatic cancer continue to die
with relatively low tumor burden when compared to
other cancer types. Ascites, whether proven to be malig-
nant or not, is a harbinger of the final stages of pancreatic
cancer. It occurs relatively infrequently, in part because
Table 1: Patient Demographics
Number of patients
Age at diagnosis 60 ± 10.4 years
% Male 87%
Location of Tumor
Head 13
Body 0
Tail 1
Unknown 1
Average size of tumor (cm)
Overall 4.2 ± 3.04 cm
Resected 2.9 ± 1.32 cm
Unresectable 4.4 ± 3.38 cm
Presentation
Resected 4
Locally Advanced 6
Metastatic 5
Ascites Diagnosed
At celiotomy 2
Physical exam 10
Radiographically 3World Journal of Surgical Oncology 2006, 4:16 http://www.wjso.com/content/4/1/16
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many patients do not survive long enough to manifest
with it. This is the first study that documents a commonly
observed clinical phenomenon; the appearance of ascites
in pancreatic cancer is associated with minimal remaining
life expectancy, regardless of prior intervention for the
treatment of the primary tumor and regardless of how the
ascites is managed.
In this study, we have looked at 15 patients obtained from
a common database composed of patients enrolled in var-
ious adjuvant and palliative protocols for pancreatic can-
cer at our institution. Most patients had tumors located in
the head of their gland, and over two thirds were unresect-
able. As one would expect, the ascites free interval was
longer in the four patients undergoing complete resection
of their tumor, but once the tumors recurred, as almost all
Table 2: Survival in months
Overall Resected Unresected p value
n 15 4 11
From diagnosis 11.2 ± 12.10 20.8 ± 20.22 7.7 ± 5.65 0.06
Ascites free 9.0 ± 12.06 20 ± 20.32 5.1 ± 3.86 0.02
With ascites 2.2 ± 2.56 0.8 ± 0.43 2.6 ± 2.85 0.24
Photomicrograph with cytologically positive specimen in a patient with pancreatic cancer and new onset ascites (hematoxylin  and eosin stain, ×1000) Figure 1
Photomicrograph with cytologically positive specimen in a patient with pancreatic cancer and new onset ascites (hematoxylin 
and eosin stain, ×1000).World Journal of Surgical Oncology 2006, 4:16 http://www.wjso.com/content/4/1/16
Page 5 of 6
(page number not for citation purposes)
do, life expectancy with ascites was less than one month.
There were no predictive indicators of who would develop
ascites based on findings at initial presentation. Patients
who were not resected did slightly better in this regard in
that they survived slightly longer after the appearance of
ascites, and this is probably a manifestation of the survival
benefit, albeit minimal, of ongoing cytotoxic chemother-
apy. Other authors have shown median survival of
approximately the same length once ascites manifests
[11]. Nonetheless, the salutary effects of systemic chemo-
therapy were not great enough to produce a meaningful
difference in survival with ascites between resected
patients who had completed their therapy months earlier
and non resected patients who were undergoing therapy
when the ascites appeared.
Tumor markers did not correlate with onset of ascites, and
this is not surprising given that only one in three patients
actually had tumor cells in their ascites fluid; perhaps this
is the most important observation that can be gleaned
from this study. Cytology does not appear to be important
– the mere presence of ascites is what really matters. Large
tumors shed tumors cells, but smaller tumor secrete
vasoactive peptides that change osmotic gradients and
cause ascites; this was probably the case in patients with
ascites and no carcinomatosis or with radiologically
occult primaries. Most patients never came to surgery to
document the presence or absence of carcinomatosis; we
presume it was present but cannot say for sure. Regardless
of whether carcinomatosis could be documented, ascites,
in and of itself, was a uniformly poor prognostic sign. This
statement is supported by the wealth of data regarding the
grave prognostic implications of positive peritoneal wash-
ings in patients with pancreatic cancer and radiologically
resectable tumors [12-15]. At our institution, routine
washings of the peritoneum are not obtained. First and
foremost, resection is pursued based upon preoperative
imaging studies and intraoperative findings since it offers
the best survival advantage. As a result of this analysis, we
now regard the presence of unexplained intraperitoneal
fluid at the time of celiotomy as an absolute contraindica-
tion to resection.
Conclusion
Based on our clinical impression and now, this study,
when we observe it, we seriously weigh the utility of con-
tinuing chemotherapy with toxic side effects. Our focus
shifts towards palliation and supportive care and,
although peritoneovenous shunts do not prolong life, we
consider them supportive care in this patient group. Any-
thing that keeps patients out of the hospital and reasona-
bly palliated can only serve to enhance the short time left
in the course of their illness.
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